Research programme: STAT3 transcription factor inhibitors - Singh Biotechnology

Drug Profile

Research programme: STAT3 transcription factor inhibitors - Singh Biotechnology

Alternative Names: SBT 100; SBT 101

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Singh Biotechnology
  • Class Antibodies; Antineoplastics
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Jun 2017 Pharmacodynamic data from a preclinical study presented at 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO 2017)
  • 04 Aug 2016 Singh Biotechnology has patent protection for STAT3 transcription factor inhibitors (Singh Biotechnology website, August 2016)
  • 03 Jun 2016 Pharmacodynamic data from a preclinical study presented at 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top